Khorramnia Saeed, Navidi Zia, Sarkoohi Ali, Iravani Mojgan Mohajeri, Orandi Amirhossein, Orandi Amirali, Ghazi Samrand Fattah, Fallah Ehsan, Malekabad Ebadallah Shiri, Moghadam Seyed Hamid Pakzad
Department of Anesthesiology, School of Medicine Rafsanjan University of Medical Sciences Rafsanjan Iran.
School of Allied Medical Sciences, 503 Hospital (Hajar) AJA University of Medical Sciences Tehran Iran.
Health Sci Rep. 2025 Jul 23;8(7):e71118. doi: 10.1002/hsr2.71118. eCollection 2025 Jul.
Remdesivir and Sotrovimab have emerged as potential treatment options for patients diagnosed with coronavirus disease 2019 (COVID-19). This systematic review and meta-analysis sought to evaluate and compare the effectiveness and safety of these two drugs in the context of COVID-19 management.
A systematic search was conducted in PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar up to July 2024. The effectiveness outcomes examined included mortality rate, hospitalization rate, emergency department visits, ICU admission, and adverse events. The risk of bias in nonrandomized studies of interventions was evaluated using a standardized tool, and data from the identified studies were meticulously analyzed using Comprehensive Meta-Analysis (CMA) software.
The analysis incorporated a total of 9 studies involving 7841 patients. The meta-analysis findings indicated no significant disparity between the Remdesivir and Sotrovimab groups concerning mortality rate (odds ratio [OR] = 3.49, 95% confidence interval [CI]: 0.50-24.11, = 0.20), hospitalization rate (OR = 2.11, 95% CI: 0.85-5.22, = 0.10), emergency department visit (OR = 0.80, 95% CI: 0.11-5.62, = 0.82), and intensive care unit (2.37, 95% CI: 0.18-29.90, = 0.50). Moreover, comparable rates of adverse events were observed across both groups (OR = 0.98, 95% CI: 0.39-2.47, = 0.97). The certainty of evidence for these findings was rated as low or moderate.
The study findings suggest that there is no significant difference in effectiveness between Remdesivir and Sotrovimab in the treatment of COVID-19 patients. Further research is needed to provide a more comprehensive comparison of these interventions for COVID-19.
瑞德西韦和索托维单抗已成为诊断为2019冠状病毒病（COVID-19）患者的潜在治疗选择。本系统评价和荟萃分析旨在评估和比较这两种药物在COVID-19治疗中的有效性和安全性。
截至2024年7月，在PubMed、Cochrane图书馆、科学网、medRxiv和谷歌学术上进行了系统检索。检查的有效性结局包括死亡率、住院率、急诊就诊、重症监护病房（ICU）入住率和不良事件。使用标准化工具评估干预措施非随机研究中的偏倚风险，并使用综合荟萃分析（CMA）软件对纳入研究的数据进行细致分析。
该分析共纳入9项研究，涉及7841例患者。荟萃分析结果表明，瑞德西韦组和索托维单抗组在死亡率（比值比[OR]=3.49，95%置信区间[CI]：0.50 - 24.11，P=0.20）、住院率（OR=2.11，95%CI：0.85 - 5.22，P=0.10）、急诊就诊（OR=0.80，95%CI：0.11 - 5.62，P=0.82）和重症监护病房入住率（OR=2.37，95%CI：0.18 - 29.90，P=0.50）方面无显著差异。此外，两组不良事件发生率相当（OR=0.98，95%CI：0.39 - 2.47，P=0.97）。这些结果的证据确定性被评为低或中等。
研究结果表明，瑞德西韦和索托维单抗在治疗COVID-19患者方面的有效性无显著差异。需要进一步研究以对这些COVID-19干预措施进行更全面的比较。
